
Repairing the intestinal epithelial barrier is paramount in the treatment of IBD.

Repairing the intestinal epithelial barrier is paramount in the treatment of IBD.

The case study of the medical mission in Peru serves as a poignant example of the indispensable role clinical pharmacists play in health care teams, especially in challenging and resource-limited environments.

In LePage v. Center for Reproductive Medicine, the Alabama Supreme Court ruled that “extrauterine embryos” are considered children, causing some infertility clinics to halt IVF processes.

Initiating and optimizing heart failure guideline-directed medical therapy is critical to the comprehensive management of heart failure.

The podcast highlights addressing misinformation, the impact of celebrity endorsements in pharmaceuticals, and the important role of pharmacists in educating patients.

Many psychedelics being studied for clinical use are not "magic mushrooms", rather clinical drugs formulated using good manufacturing practice standards.

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

Gepotidacin was compared with the combination of ceftriaxone and azithromycin in adolescent and adult patients with uncomplicated urogenital gonorrhea.

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

The results were presented as a late-breaking poster presentation at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

The new indication includes individuals with HIV who have suppressed viral loads with known or suspected M184V/I resistance.

Investigators found genetic evidence that certain sleep behaviors can be risk factors for lifespan.

“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

The evolution of pharmacy, as a practice and profession, is unique in that its evolution has quickened exponentially in just the past 20 years.

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

Malaria has a large global burden, affecting hundreds of millions of people each year.

Teclistamab was previously approved in October 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

Smoking 20 cigarettes per day significantly increased risk of death caused by certain types of melanomas.

Datopotamab deruxtecan is an investigational TROP2 directed antibody drug conjugate that showed positive survival impact compared to chemotherapy.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

However, increasing dietary niacin did not reduce risk of mortality from cardiovascular disease, the primary cause of death associated with nonalcoholic fatty liver disease.

Living organisms rely on iron for survival and replication. Can new research discoveries disrupt C. difficile’s ability to maintain iron homeostasis?

Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.

Cardioprotective antihyperglycemic agents are underutilized for inpatient care in heart failure patients. Lack of use can lead to preventable patient deaths and hospital readmissions.

The pharmacist’s role may vary across different practices and institutions.

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.